A Study of LY4064809 in Healthy Adult Participants

Exclusion Criteria

• •History or presence of any of the following conditions, deemed clinically significant by the investigator (or designee):
• •* metabolic disease, including congenital non-hemolytic hyperbilirubinemia, for example, Gilbert syndrome
• •* bile duct disease, including removal of the gall bladder
• •* digestive system disease
• •* blood disease
• •* disease of the nervous system
• •* significant history of, or presence of, liver disease, including any abnormal liver function tests
• •* heart disease
• •Have an abnormal electrocardiogram (ECG) at screening or admission
• •History of a major surgical procedure within 30 days prior to screening
• •Diagnosed or treated cancer within 5 years prior to screening, with the exception of the following cancers cured through treatment: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and in situ carcinoma of the cervix cured through surgery
• •* Clinically significant history of multiple or severe drug hypersensitivity reactions or drug allergies, as determined by the investigator
• •Have used or plan to use medication within 14 days prior to admission, or plan to use during the study with the exception of acetaminophen
• •Have creatinine lab clearance less than 90mL/min calculated using the Cockroft-Gault equation at screening
• •Have a positive Hepatitis B surface antigen (HBsAg), hepatitis C virus antibody or human immunodeficiency virus 1 and 2 antibody results at the screening visit